Steven E. North, Esq. and Laurence M. Deutsch, Esq.
Prostate cancer kills. The early diagnosis of that condition can save lives. The traditional way to monitor and manage a man’s prostate cancer risk is the Prostate-Specific Antigen (PSA) screening, a simple blood test that serves as a reliable guide. The results indicate whether a person’s PSA value is above the accepted norm or whether the relative increase in value over a short period of time is more than it should be.
Some relatively recent studies, however, recommend against routine PSA screenings.
While there are legitimate concerns that a prostate biopsy should not be taken lightly, the initial information from a PSA test is still the accepted standard of care. Further, we believe that studies are sometimes promulgated with the intent of saving money (cost of a routine PSA test) even though identifying the cancer early in some patients could mean the difference between life and death.
What people of that point of view fail to recognize and appreciate is that until PSA screening became the standard in the late 1980’s, more than half the men diagnosed with prostate cancer already had advanced disease that had metastasized to other parts of the body. One would think that nothing more need be said.
Nevertheless, these studies have influenced primary care physicians, some of whom are not screening patients as frequently as they used to. The bottom line, in our opinion, is that having or bypassing a PSA screening is a patient’s choice. If a doctor feels that the financial benefit outweighs the potential health risk, it is still the patient who should decide whether the simple blood test, the current standard of care, should be administered.
When the decision is to run the test and the results indicate high PSA values, there will be treatment considerations. For some, the best option may be “watchful waiting” for less aggressive cancers. For others, some form of radiation or surgery should be undertaken.
Medical malpractice cases concerning prostate cancer often do not center around when the PSA testing was or should have been done. Most often it is about the failure of a clinician to appreciate a significant abnormality and take action with respect to it. We have successfully litigated numerous prostate cancer cases in which, for apparently unexplained reasons other than simple carelessness, the physician failed to act on significantly abnormal results which led to the development of advanced prostate cancer.
Cleveland Clinic Men’s Health advisor, March 27, 2017
Back to Medical Malpractice Attorney NYC
By NYC Attorney of Your Medical Malpractice Claim
Phone (212) 861-5000
By Email : Click here
We thank you for your Negotiating tenacity... The award was so much more than either Denise or I anticipated... Read more.
Sally and Denise
Specialist in Cases Involving Significant Damages • Listed in Best Lawyers • Listed in Who’s Who • Commentator, Court T.V., Eyewitness News, Talk News T.V. • Contributing Author, New York Law Journal Author of Numerous Publications • Faculty Chairman, Continuing Legal Education Programs • Trial Lawyer and Bar Association Committees
1988, New York and U.S. District Court, Northern, Southern, Eastern and Western Districts of New York. Union College, Schenectady, B.A., magna cum laude, 1984 Phi Beta Kappa; University of Chicago Law School, J.D., 1987
Receive a complimentary consultation from one of our experienced attorneys.